Evidence map›Paper›PMID 30231694›Full record

ArticleTechnology in cancer research & treatment2018

MicroRNA-19b Promotes Nasopharyngeal Carcinoma More Sensitive to Cisplatin by Suppressing KRAS.

Yuan Zhang, Yulin Zhao, Lei Liu, Hongxia Su, Dong Dong, Jia Wang, Yaqian Zhang, Qi Chen, Chang Li

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Technology in cancer research & treatment, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Cells · 2023
    Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Yuan Zhang1 Department of Rhinology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.ORCID 0000-0002-9551-7621
Yulin Zhao1 Department of Rhinology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Lei Liu1 Department of Rhinology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Hongxia Su1 Department of Rhinology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Dong Dong1 Department of Rhinology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Jia Wang1 Department of Rhinology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Yaqian Zhang1 Department of Rhinology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Qi Chen1 Department of Rhinology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Chang Li1 Department of Rhinology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
First Affiliated Hospital of Zhengzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MicroRNAs have been reported to play a vital role in diverse biological processes and tumorigenesis. MicroRNA-19b-5p has been observed to be downregulated in other cancers, but the function of microRNA-19b-5p in human nasopharyngeal carcinoma has not been well investigated. In our study, these results demonstrated that microRNA-19b-5p was significantly downregulated in 37 pairs of nasopharyngeal carcinoma tissues when compared to normal tissues. Enforced expression of microRNA-19b-5p inhibited activity of cell proliferation and cell migration of nasopharyngeal carcinoma cancer cells, CNE1 and HNE1. Furthermore, microRNA-19b-5p targeted KRAS proto-oncogene, GTPase in cancer cells. In human clinical specimens, KRAS was higher expressed in cancer tissues when compared with normal tissues, which was inversely correlated with the expression of microRNA-19b-5p. More interestingly, microRNA-19b-5p sensitizes CNE1 cells to cisplatin by inhibiting its target KRAS. Finally, microRNA-19b-5p inhibits tumorigenesis in vivo. Thus, our results investigated that microRNA-19b-5p functioned as a tumor suppressor and indicated its potential application for the treatment of human nasopharyngeal carcinoma in future.

Indexed as

CarcinogenesisCell Line, TumorCell MovementCell ProliferationCisplatinDown-RegulationGene Expression Regulation, NeoplasticHEK293 CellsHumansMicroRNAsNasopharyngeal CarcinomaProto-Oncogene MasProto-Oncogene Proteins p21(ras)CisplatinKRAS protein, humanMAS1 protein, humanMicroRNAsMIRN19A microRNA, humanProto-Oncogene MasProto-Oncogene Proteins p21(ras)chemosensitivitycisplatinKRASmiRNA-19bnasopharyngeal carcinoma

Identifiers

PMID30231694
PMCPMC6149031
OpenAlexW2892157950

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.